Peptide inhibitors of IASPP

Details Peptide inhibitors of IASPP Peptide inhibitors of IASPP

2008-03-05

2010-06-29

Aeder, Sean E (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Reexamination Certificate

active

07745571

ABSTRACT:
The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide.

REFERENCES:
patent: 6582933 (2003-06-01), Okamoto
patent: WO 00/55175 (2000-09-01), None
patent: WO 01/07082 (2001-02-01), None
Dippold et al (PNAS, Mar. 1981, 78(3): 1695-1699).
Amalfitano et al., “Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy,”Current Gene Therapy, 2:111-133 (2002).
Bergamaschi et al., “iASPP Oncoprotein is a Key Inhibitor of p53 Conserved From Worm to Human,”Nature Genet. 33:162-167 (2003).
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”J. Cell Biol. 111:2129-2138 (1990).
Database NCBI ′Online!′ Accession No. NP—006654 (2003).
Database NCBI ′Online!′ Accession No. NP—505955 (2003).
Houdebine, “Production of pharmaceutical proteins from transgenic animals,”Jour. of Biotechnology, 34:269-287 (1994).
Iwabuchi et al., “Stimulation of p53-Mediated Transcriptional Activation by the p53-Binding Proteins, 53BP1 and 53BP2,”J. Biol. Chem. 273:26061-26068 (1998).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Mol. Cell Biol., 8:1247-1252 (1998).
Naumovski and Cleary, “The p53-Binding Protein 53BP2 Also Interacts with BcI2 and Impedes Cell Cycle Progression at G2/M,”Mol. Cell. Biol. 16:3884:3892 (1996).
Pandha et al., “Oncological applications of gene therapy,”Current Opinion in Investigational Drugs, 1(1):122-134 (2000).
Samuels-Lev et al., “ASPP Proteins Specifically Stimulate the Apoptotic Function of p53,”Mol. Cell, 8:781-794 (2001).
Slee and Lu, “The ASPP Family: Deciding Between Life and Death After DNA Damage,”Toxicol. Lett. 139:81-87 (2003).
Stiewe et al., “Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis,”J. Biol. Chem., 277(16):14177-85 (2002).
Takada et al., “ReIA-Associated Inhibitor Blocks Transcription of Human Immunodeficiency Virus Type 1 by Inhibiting NF-κB and Sp1 Actions,”J. Virol. 76:8019-8030 (2002).
Verma et al., “Gene therapy—promises, problems and prospects,”Nature, 389:239-242 (1997).

Affiliated with

Also associated with

Rating

Peptide inhibitors of IASPP does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide inhibitors of IASPP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of IASPP will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4231544